gvhd-cme.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Home - The role of ECP in the management of |
| Description | GvHD Hub Symposium: The role of ECP in the management of |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 143.198.242.159 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
gvhd-cme.com Valuation
|
US$1,592
Last updated: 2023-05-20 05:10:39
gvhd-cme.com has Semrush global rank of 0. gvhd-cme.com has an estimated worth of US$ 1,592, based on its estimated Ads revenue. gvhd-cme.com receives approximately 183 unique visitors each day. Its web server is located in United States, with IP address 143.198.242.159. According to SiteAdvisor, gvhd-cme.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,592 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$44 |
| Yearly Ads Revenue | US$529 |
| Daily Unique Visitors | 12 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| gvhd-cme.com. | A | 3600 | IP: 143.198.242.159 |
| gvhd-cme.com. | NS | 1800 | NS Record: ns1.digitalocean.com. |
| gvhd-cme.com. | NS | 1800 | NS Record: ns2.digitalocean.com. |
| gvhd-cme.com. | NS | 1800 | NS Record: ns3.digitalocean.com. |
HtmlToTextCheckTime:2023-05-20 05:10:39
| Home Agenda Learning Objectives About us Register GvHD HUB Home Agenda Learning Objectives About us Register GvHD Hub The role of ECP in the management of GvHD An EBAC Accredited Educational Programme Tuesday, November 29, 2022 17:00 — 19:00 CET Free registration here Add to calendar LIVE VIRTUAL SYMPOSIUM This 2-hour symposium, chaired by Professor Mohamad Mohty, will provide an opportunity for participants to interact with a world-renowned faculty and hear their expert recommendations on treating patients with graft-versus-host disease (GvHD) using extracorporeal photopheresis (ECP). GvHD is a major complication of allogeneic hematopoietic stem cell transplantation, a curative treatment for many hematologic cancers and other disorders. A long-standing treatment for GvHD is ECP, which, unlike other second-line therapies, is not immunosuppressive, has no reported drug interactions, and does not have a negative impact on the graft-versus-malignancy effect of the transplant. 1 ECP is |
HTTP Headers
HTTP/1.1 308 Permanent Redirect Date: Wed, 11 Jan 2023 09:16:40 GMT Content-Type: text/html Content-Length: 164 Connection: keep-alive Location: https://gvhd-cme.com HTTP/2 200 date: Wed, 11 Jan 2023 09:16:40 GMT content-type: text/html; charset=utf-8 content-length: 118720 x-powered-by: Next.js etag: "1cfc0-pQF+Xi1sFmNhcHEM9U1D/N9N4KQ" cache-control: private, no-cache, no-store, max-age=0, must-revalidate vary: Accept-Encoding strict-transport-security: max-age=15724800; includeSubDomains |